Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv. Here’s a perspective on the current climate in which your government affairs team works. As you read this list of observations, imagine you’re a lawmaker and try to find where the ACR’s agenda fits into the current landscape: Washington is highly…
Search results for: biosimilar
How to Be Heard: Tips for Efficient & Effective Advocacy
Did you know that there are more state legislators in this country than practicing rheumatologists? There are more than 7,300 state legislators alone, and each represents tens of thousands of constituents. As providers, you have a unique expertise that can be valuable to legislators in making decisions on biosimilars, research funding, insurance reform and a…
S.C. Rheumatism Society Benefits from ACR Partnership
Editor’s note: This article will be the first in a series of articles highlighting the advocacy work done by state and local societies around the country. The South Carolina Rheumatism Society (SCRS) realizes multiple benefits from its association with the ACR, according to Jeffrey G. Lawson, MD, the society’s treasurer. One example of the support offered:…
AHCA, ACR Health Policy & More
Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv. What a month! House Republicans introduced their bill to repeal and replace Obamacare. The ACR has analyzed the bill and believes the American Health Care Act (AHCA) does not go far enough to help Americans with rheumatic diseases. Brief recap: The…
A New Administration Brings Updated ACR Policy Positions
The ACR continues to broaden its advocacy efforts on issues critical to rheumatology, as described in updates to its 2017 health policy statements. Along with continuing to advocate for access to care and treatments, enhancements to rheumatology research and training the next generation of rheumatologists, the 2017 health policy statements address a number of new…
ACR Puts Forward Principles on Patient Access to Care
As the 115th Congress and the Trump administration consider potential reforms to the healthcare system, including actions related to the Affordable Care Act (ACA), physicians around the country remain vitally concerned about the need to preserve and improve access to care for their patients. To that end, the ACR continues to lobby for policies that…
ACR Urges CMMI to Test Transparently: Coalition offers principles to guide CMS’s care innovation efforts
The Center for Medicare and Medicaid Innovation (CMMI), which develops concepts for healthcare payment and service delivery, must be transparent and engaged with all stakeholders as it tests new models, according to a coalition of 30 associations. On Feb. 10, the Healthcare Leaders for Accountable Innovation in Medicare Coalition, which includes the ACR, released six…
The ACR Supports Practicing Rheumatologists
A new presidential administration took office in January 2017. Although no one truly knows what directions our government and economy will take, one projection is that healthcare regulatory and insurance coverage policies will change, possibly dramatically. In a time of uncertainty, rheumatologists and rheumatology health professionals can turn to the ACR/ARHP for support, guidance and…
U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales
NEW YORK (Reuters)—The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the…
Top ACR Priorities in 2017 Include Drug Costs, MACRA
With a new federal administration and Republican-controlled Congress taking the helm in 2017, the ACR Government Affairs Committee has identified top legislative and regulatory priorities for the year. “The main priority is going to be helping represent the rheumatology community as Medicare is reformed, because the era of MACRA started Jan. 1,” says Angus Worthing,…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 38
- Next Page »